HighTower Advisors’s Oragenics OGEN Stock Holding History

HighTower Advisors’s Portfolio OGEN Stock Details OGEN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-50	Closed	-$20K	–	3458
2022 Q3	$20K	Hold	50	–	–	﹤0.01%	2972
2022 Q2	$31K	Buy	+50	New	+$28.9K	﹤0.01%	2963

Other funds holding OGEN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SBF

Sara-Bay Financial Sarasota, Florida $375M AUM 56.53% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

HighTower Advisors's OGEN Position: Q4 2022 in Review

HighTower Advisors sold out of Oragenics (OGEN) in Q4 2022, closing a stake of 50 shares — an estimated $20K sold.

HighTower Advisors first reported a position in OGEN in Q2 2022 and held it in 2 quarters. The position peaked at $31K in Q2 2022. 24 funds tracked by Wall St. Rank hold OGEN as of Q4 2022.

HighTower Advisors reported no remaining Oragenics position as of Q4 2022 after selling out during the quarter.
HighTower Advisors sold 50 Oragenics shares in Q4 2022, an estimated $20K.
HighTower Advisors first reported a position in Oragenics in Q2 2022 and held it in 2 quarters.
HighTower Advisors's Oragenics position peaked at $31K in Q2 2022.
24 funds tracked by Wall St. Rank held Oragenics as of Q4 2022.

Based on HighTower Advisors's 13F filing for Q4 2022, filed 9 Feb 2023.